AGTC develops therapeutics for patients with unmet medical needs utilizing the non-pathogenic adeno-associated virus to deliver therapeutic genes. AGTC secured rights to a portfolio of strategically vital intellectual property in the application of Adeno-Associated Virus to gene therapy. AGTC has signed licenses to over 40 U.S. and foreign patents, and has five products in active development